|
US2020253901A1
|
|
Stable dosage forms of levomilnacipran
|
|
US2018303853A1
|
|
Compositions and methods for treating bacterial infections using ceftaroline
|
|
CN105555257A
|
|
Micronized pharmaceutical compositions
|
|
AU2012203789A1
|
|
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
CA2780403A1
|
|
Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
|
|
CA2716914A1
|
|
Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
|
|
CA2753387A1
|
|
Novel cephem compounds useful for the treatment of bacterial infections
|
|
BRPI0909181A2
|
|
compound, pharmaceutical composition, and condition treatment method that responds to stearoyl coa desaturase inhibitor
|
|
AU2003284005A1
|
|
Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
|
|
AU2003225206A1
|
|
Prevention and treatment of functional somatic disorders, including stress-related disorders
|
|
AU2003225837A1
|
|
NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
|
